We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.605 | 1.39% | 44.055 | 44.33 | 43.96 | 44.13 | 2,317,002 | 20:32:29 |
From May 2022 to May 2024
By Michael Susin
GSK PLC said Tuesday that it has reached an agreement to buy the late-stage biopharmaceutical company BELLUS Health Inc. for $14.75 a share in cash, representing a total equity value of around $2.0 billion.
The pharmaceutical giant said the deal will provide access to camlipixant, a treatment for refractory chronic cough currently in phase III development.
Following the anticipated regulatory approval and launch of camlipixant in 2026, the acquisition of the Canada-based company is expected to be accretive to adjusted earnings per share--which strips out exceptional and other one-off items--from 2027 and has the potential to deliver significant sales through 2031 and beyond, it added.
"This proposed acquisition complements our portfolio of specialty medicines and builds on our expertise in respiratory therapies," Chief Commercial Officer Luke Miels said.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
April 18, 2023 02:33 ET (06:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
